[Editorial: When is EEG indicated?]

Same author

Noncanonical effector functions of the T-memory-like T-PLL cell are shaped by cooperative TCL1A and TCR signaling.

Blood·2020

Same author

Corrections: Reinstated p53 response and high anti-T-cell leukemia activity by the novel alkylating deacetylase inhibitor tinostamustine.

Leukemia·2020

Same author

Reinstated p53 response and high anti-T-cell leukemia activity by the novel alkylating deacetylase inhibitor tinostamustine.

Leukemia·2020

Same author

Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL.

Nature communications·2018

Same author

Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.

Leukemia·2017

Same author

Antagonism of NMDA receptors as a potential treatment for Down syndrome: a pilot randomized controlled trial.

Translational psychiatry·2012

Same journal

[Effectiveness of buflomedil in arterial occlusive disease. Modification of transcutaneous oxygen pressure in a placebo-controlled double-blind study].

MMW, Munchener medizinische Wochenschrift·1984

Same journal

[Retroperitoneal ganglioneuroma].

MMW, Munchener medizinische Wochenschrift·1984

Same journal

[Is intravenous oxygen therapy defensible? Reflections on 2 cases with severe side effects of such treatment].

MMW, Munchener medizinische Wochenschrift·1984

Same journal

[The oncologic emergency. Surgical therapy of ascites, including tumor ascites].

MMW, Munchener medizinische Wochenschrift·1984

Same journal

[Outside methods. Cytoplasmic therapy of malignant tumors with macromolecular organ extracts].

MMW, Munchener medizinische Wochenschrift·1984

Same journal

[Family of the cancer patient].

MMW, Munchener medizinische Wochenschrift·1984

Related Experiment Videos

[Editorial: When is EEG indicated?]

Related Concept Videos

Noncanonical effector functions of the T-memory-like T-PLL cell are shaped by cooperative TCL1A and TCR signaling.

Corrections: Reinstated p53 response and high anti-T-cell leukemia activity by the novel alkylating deacetylase inhibitor tinostamustine.

Reinstated p53 response and high anti-T-cell leukemia activity by the novel alkylating deacetylase inhibitor tinostamustine.

Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL.

Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.

Antagonism of NMDA receptors as a potential treatment for Down syndrome: a pilot randomized controlled trial.

[Effectiveness of buflomedil in arterial occlusive disease. Modification of transcutaneous oxygen pressure in a placebo-controlled double-blind study].

[Retroperitoneal ganglioneuroma].

[Is intravenous oxygen therapy defensible? Reflections on 2 cases with severe side effects of such treatment].

[The oncologic emergency. Surgical therapy of ascites, including tumor ascites].

[Outside methods. Cytoplasmic therapy of malignant tumors with macromolecular organ extracts].

[Family of the cancer patient].

Related Experiment Videos

[Editorial: When is EEG indicated?]

Related Concept Videos

Related Articles

Noncanonical effector functions of the T-memory-like T-PLL cell are shaped by cooperative TCL1A and TCR signaling.

Corrections: Reinstated p53 response and high anti-T-cell leukemia activity by the novel alkylating deacetylase inhibitor tinostamustine.

Reinstated p53 response and high anti-T-cell leukemia activity by the novel alkylating deacetylase inhibitor tinostamustine.

Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL.

Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.

Antagonism of NMDA receptors as a potential treatment for Down syndrome: a pilot randomized controlled trial.

[Effectiveness of buflomedil in arterial occlusive disease. Modification of transcutaneous oxygen pressure in a placebo-controlled double-blind study].

[Retroperitoneal ganglioneuroma].

[Is intravenous oxygen therapy defensible? Reflections on 2 cases with severe side effects of such treatment].

[The oncologic emergency. Surgical therapy of ascites, including tumor ascites].

[Outside methods. Cytoplasmic therapy of malignant tumors with macromolecular organ extracts].

[Family of the cancer patient].